Beyond resumption of the Japanese Government's recommendation of the HPV vaccine

Lancet Oncol. 2018 Dec;19(12):1563-1564. doi: 10.1016/S1470-2045(18)30573-4.

Authors

Yutaka Ueda¹, Asami Yagi², Sayaka Ikeda³, Takayuki Enomoto⁴, Tadashi Kimura²

Affiliations

¹ Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan. Electronic address: y.ueda@gyne.med.osaka-u.ac.jp.
² Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
³ Department of Gynecology, Tama-Hokubu Medical Center, Higashimurayama, Tokyo, Japan.
⁴ Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

PMID: 30507414
DOI: 10.1016/S1470-2045(18)30573-4

No abstract available

MeSH terms

Adolescent
Age Factors
Child
Female
Government Regulation*
Health Policy / legislation & jurisprudence*
Humans
Japan / epidemiology
Papillomavirus Infections / diagnosis
Papillomavirus Infections / epidemiology
Papillomavirus Infections / prevention & control*
Papillomavirus Infections / virology
Papillomavirus Vaccines / administration & dosage*
Papillomavirus Vaccines / adverse effects
Policy Making
Protective Factors
Risk Factors
Sex Factors
Time Factors
Treatment Outcome
Uterine Cervical Neoplasms / diagnosis
Uterine Cervical Neoplasms / epidemiology
Uterine Cervical Neoplasms / prevention & control*
Uterine Cervical Neoplasms / virology
Vaccination / legislation & jurisprudence*

Substances

Papillomavirus Vaccines